| # | Title | Journal | Year | Citations |
|---|
| 1 | Vaccine hesitancy: Definition, scope and determinants | Vaccine | 2015 | 3,286 |
| 2 | Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity | Vaccine | 2012 | 1,503 |
| 3 | Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012 | Vaccine | 2014 | 1,439 |
| 4 | The annual impact of seasonal influenza in the US: Measuring disease burden and costs | Vaccine | 2007 | 1,425 |
| 5 | Global Burden of Human Papillomavirus and Related Diseases | Vaccine | 2012 | 1,254 |
| 6 | The Biology and Life-Cycle of Human Papillomaviruses | Vaccine | 2012 | 1,042 |
| 7 | Chapter 2: The burden of HPV-related cancers | Vaccine | 2006 | 1,029 |
| 8 | Chapter 1: HPV in the etiology of human cancer | Vaccine | 2006 | 933 |
| 9 | Antibody response to influenza vaccination in the elderly: A quantitative review | Vaccine | 2006 | 926 |
| 10 | The mucosal immune system: from fundamental concepts to vaccine development | Vaccine | 1992 | 856 |
| 11 | Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? | Vaccine | 2020 | 828 |
| 12 | Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination | Vaccine | 2009 | 813 |
| 13 | A postmodern Pandora's box: Anti-vaccination misinformation on the Internet | Vaccine | 2010 | 811 |
| 14 | The biology of influenza viruses | Vaccine | 2008 | 802 |
| 15 | Evidence for antibody as a protective correlate for COVID-19 vaccines | Vaccine | 2021 | 766 |
| 16 | Nanoparticle vaccines | Vaccine | 2014 | 737 |
| 17 | Anti-vaccine activists, Web 2.0, and the postmodern paradigm – An overview of tactics and tropes used online by the anti-vaccination movement | Vaccine | 2012 | 734 |
| 18 | Strategies for addressing vaccine hesitancy – A systematic review | Vaccine | 2015 | 734 |
| 19 | Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer | Vaccine | 2012 | 695 |
| 20 | An overview of the epidemiology of avian influenza | Vaccine | 2007 | 675 |
| 21 | Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia | Vaccine | 2008 | 658 |
| 22 | Placental transport of immunoglobulin G | Vaccine | 2003 | 627 |
| 23 | Global epidemiology of meningococcal disease | Vaccine | 2009 | 622 |
| 24 | A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines | Vaccine | 2012 | 610 |
| 25 | Measuring vaccine hesitancy: The development of a survey tool | Vaccine | 2015 | 593 |
| 26 | Influenza vaccine: The challenge of antigenic drift | Vaccine | 2007 | 568 |
| 27 | Vaccine hesitancy and healthcare providers | Vaccine | 2016 | 551 |
| 28 | Adjuvants—a classification and review of their modes of action | Vaccine | 1997 | 537 |
| 29 | Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries | Vaccine | 2008 | 526 |
| 30 | Neonatal and early life vaccinology | Vaccine | 2001 | 513 |
| 31 | Factors associated with uptake of vaccination against pandemic influenza: A systematic review | Vaccine | 2011 | 507 |
| 32 | Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic | Vaccine | 2020 | 498 |
| 33 | Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data | Vaccine | 2011 | 496 |
| 34 | Adjuvants for human vaccines—current status, problems and future prospects | Vaccine | 1995 | 485 |
| 35 | Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey | Vaccine | 2021 | 469 |
| 36 | Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development | Vaccine | 2012 | 466 |
| 37 | Adjuvants — a balance between toxicity and adjuvanticity | Vaccine | 1993 | 464 |
| 38 | Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information | Vaccine | 2015 | 440 |
| 39 | Hepatitis A virus seroprevalence by age and world region, 1990 and 2005 | Vaccine | 2010 | 434 |
| 40 | Immune responses to human papillomavirus | Vaccine | 2006 | 431 |
| 41 | The annual production cycle for influenza vaccine | Vaccine | 2003 | 430 |
| 42 | Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases | Vaccine | 2006 | 427 |
| 43 | Strategies intended to address vaccine hesitancy: Review of published reviews | Vaccine | 2015 | 424 |
| 44 | TLR-based immune adjuvants | Vaccine | 2011 | 418 |
| 45 | Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only | Vaccine | 2006 | 417 |
| 46 | Vaccine adjuvants revisited | Vaccine | 2007 | 417 |
| 47 | Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) | Vaccine | 2015 | 416 |
| 48 | Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space | Vaccine | 2000 | 412 |
| 49 | Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis | Vaccine | 1998 | 408 |
| 50 | The test-negative design for estimating influenza vaccine effectiveness | Vaccine | 2013 | 406 |
